Lundbeck Explored Acquisition of Chicago-based Xeris Biopharma
Danish drugmaker Lundbeck has initiated interest in acquiring Xeris, a firm focused on endocrine and neuromuscular therapies.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you believe pharmaceutical industry mergers generally result in better outcomes for patients?
Danish pharmaceutical company Lundbeck has reportedly engaged advisers to explore a potential takeover of Chicago-based Xeris Biopharma. The move signals a potential expansion in the rare disease and endocrine therapy sectors.
Why it matters
A successful acquisition would combine Lundbeck’s psychiatric and neurological portfolio with the specialized commercial assets of Xeris. For operators, this indicates ongoing consolidation trends among mid-market pharmaceutical firms seeking to diversify their therapeutic pipelines.
Xeris Biopharma reported $91 million in revenue for the second quarter, fueling a current market capitalization of $1.79 billion. These figures accompany a report that Lundbeck is assessing the company as a potential acquisition target.
The players
Lundbeck
A Denmark-based pharmaceutical company that specializes in the development and distribution of therapies for psychiatric and neurological disorders.
Xeris Biopharma
A Chicago-based biotechnology firm focused on developing and commercializing specialized therapies for endocrine and rare neuromuscular conditions.
The details
Lundbeck is reportedly working with external advisers to evaluate the feasibility of bringing the Chicago-based firm into its organization. Xeris currently maintains a commercial portfolio featuring three primary therapies: Recorlev, Gvoke, and Keveyis. This potential integration would augment Lundbeck’s existing therapeutic focus on psychiatric and neurological disorders, such as Rexulti and Vyepti, by adding specialized endocrine and rare neuromuscular treatments.
Timeline
August 2026: Xeris Biopharma reported $91 million in second-quarter revenue.
August 2026: Lundbeck reported stronger-than-expected second-quarter sales.
September 29, 2026: Bloomberg News reported on Lundbeck's interest in the acquisition.
Market Landscape
The potential deal follows the 2024 acquisition of Amgen's Horizon Therapeutics as a primary industry precedent. It signals that established pharmaceutical companies continue to prioritize the acquisition of specialized therapeutic portfolios to bolster long-term competitive positions.
Operators in the pharmaceutical and biotech space should monitor for official deal confirmation, as such acquisitions typically trigger significant shifts in supply chain management and R&D priorities. Firms should review their own therapeutic portfolios to assess potential synergies or competitive threats posed by such consolidations.
The takeaway
Large-scale acquisitions remain a standard strategy for global firms looking to scale their R&D capabilities through smaller, specialized assets. Management should track the valuation multiples of peers in the endocrine and rare disease space as a barometer for potential future buyout activity.
Further reading
For more on local biotech developments and industry shifts, visit the Healthcare section.
Live Poll
Do you believe pharmaceutical industry mergers generally result in better outcomes for patients?
